POOLBEG PHARMA PLC - POLBF STOCK NEWS

Welcome to our dedicated page for POOLBEG PHARMA PLC news (Ticker: POLBF), a resource for investors and traders seeking the latest updates and insights on POOLBEG PHARMA PLC stock.

Poolbeg Pharma PLC (POLBF) delivers innovative therapies for diseases with critical unmet needs, from cancer immunotherapy complications to rare disorders. This news hub provides investors and industry observers with essential updates on clinical developments, regulatory progress, and strategic partnerships.

Track POLBF's advancements through verified reports on clinical trial results, patent approvals, and collaboration agreements. Our curated collection includes earnings announcements, research breakthroughs, and analysis of pipeline candidates like POLB 001 for cytokine management.

This resource serves as your central reference for understanding Poolbeg Pharma's position in biopharmaceutical innovation. Discover updates spanning orphan drug designations, AI-driven research initiatives, and global licensing opportunities while maintaining compliance with financial disclosure standards.

Bookmark this page for streamlined access to POLBF's evolving story. Check regularly for authoritative reporting on therapies addressing severe influenza, Behçet's disease, and oncology-related challenges.

03/20/2024 03:00 AM

News

Poolbeg Pharma PLC Announces POLB 001 US Patent Update

Rhea-AI Summary

Poolbeg Pharma (POLBF) receives a Notice of Allowance for its Immunomodulator II patent application in the United States, strengthening its intellectual property portfolio. The patent covers the potential use of POLB 001, a Phase II-ready p38 MAP kinase inhibitor, in treating hypercytokinaemia and preventing cytokine storms. This development enhances the company's value for potential pharma partners and expands its patent portfolio, particularly in cancer immunotherapies. CEO Jeremy Skillington highlights the significance of this milestone, emphasizing the potential market impact and the unmet medical need in cancer immunotherapy-induced Cytokine Release Syndrome.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

02/22/2024 02:00 AM

News

Poolbeg Pharma PLC Announces Director/PDMR Shareholding

Rhea-AI Summary

Poolbeg Pharma (POLBF) CEO Jeremy Skillington purchases 154,764 ordinary shares, representing 0.17% of the company's issued share capital. The purchase was made at a price of 10.8 pence per share, indicating confidence in the company's future.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

02/19/2024 09:15 AM

News

Poolbeg Pharma PLC Announces Director Share Purchase

Rhea-AI Summary

Poolbeg Pharma announces Cathal Friel's purchase of 830,000 ordinary shares at 11.68 pence per share, increasing his stake to 7.4% of the Company's issued share capital.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

02/15/2024 02:00 AM

News

Poolbeg Pharma PLC Announces Board Role Change and Launch of EIP

Rhea-AI Summary

Poolbeg Pharma announces a change in Board role and approval of an Employee Performance Incentive Plan. Cathal Friel becomes Executive Chairman, and an EIP is adopted to align objectives with shareholders. The plan awards long-term incentive options to key senior management. The company focuses on rare diseases and profitable revenues, with a strong management team in place for growth and value creation.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

02/12/2024 02:00 AM

News

Poolbeg Pharma PLC Announces Market Opportunity for POLB 001 for CRS

Rhea-AI Summary

Poolbeg Pharma announces a >$10 billion market opportunity for POLB 001 in Cancer Immunotherapy-Induced CRS, supported by independent research. The company aims to focus on Rare and Orphan Diseases, leveraging the expertise of the former Amryt team. POLB 001 shows promise in addressing CRS induced by CAR-T and BsAb treatments, with potential cost-saving benefits and improved patient access to therapies.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

01/17/2024 02:00 AM

News

Poolbeg Pharma PLC Announces Further Data Shows POLB001 Potential in Cancer CRS

Rhea-AI Summary

Poolbeg Pharma announces promising in vivo results for POLB 001 in addressing cancer immunotherapy-induced CRS. POLB 001 demonstrated efficacy in reducing CRS symptoms in an animal model, with potential market opportunity estimated at over US$1 billion. Independent Advisory Board supports POLB 001's potential as an oral therapy to address unmet medical need.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

12/20/2023 02:00 AM

News

Poolbeg Pharma PLC Announces RSV AI Drug Candidate Analysis Update

Rhea-AI Summary

Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF) announces positive lab-based analysis and successful prioritization of RSV drug candidates, reflecting the high potential of its AI-led program.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

12/11/2023 02:00 AM

News

Poolbeg Pharma PLC Announces POLB 001 Data Presented at ASH

Rhea-AI Summary

Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF) presented key insights at the 65th American Society of Hematology Annual Meeting and Exposition regarding their potential therapy, POLB 001, for Cytokine Release Syndrome (CRS) associated with cancer immunotherapies. The poster detailed positive results from the LPS human challenge trial, demonstrating good safety and tolerability, a clear dose-response relationship, and a reduction in pro-inflammatory cytokines. Phase II trial enabling activities are underway with strong interest from potential pharma partners.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

11/30/2023 02:00 AM

News

Poolbeg Pharma PLC Announces Directorate Change

Rhea-AI Summary

Poolbeg Pharma (POLB) announces the resignation of Patrick Ashe, Independent Non-Executive Director, and the appointment of Eddie Gibson as Chair of the Audit & Risk Committee and Prof Brendan Buckley as Chair of the Remuneration Committee. The company is on an upward trajectory with a robust pipeline of high-value programs and aims to replicate the success of former Amryt Pharma plc leadership members recently appointed to the Poolbeg team. With strong financials, excellent clinical results, and productive partnering discussions, Poolbeg is well-positioned to generate significant shareholder value.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

11/21/2023 02:00 AM

News

Poolbeg Pharma PLC Announces Immunomodulator II Patent Granted in Japan

Rhea-AI Summary

Poolbeg Pharma (POLB) has received official decision from the Japanese Patent Office to grant Poolbeg's Immunomodulator II patent application, further strengthening the Company's robust intellectual property in the territory. Additionally, the fully granted patent for Immunomodulator I has been received from the Japanese Patent Office. Poolbeg has a worldwide license for POLB 001 for all uses in humans and is developing a strong IP portfolio with patents in place, covering the use of p38 MAP kinase inhibitors for the treatment of severe influenza and hypercytokinemia, as well as alongside cancer immunotherapies.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags